EHA 2023 | Exploring the safety & efficacy of magrolimab plus oral decitabine/cedazuridine in MDS
In this video, Amer Zeidan, MBBS, Yale University, New Haven, CT, shares some insights into a Phase II study which will explore the safety and efficacy of magrolimab in combination with oral decitabine and cedazuridine in patients with intermediate to very high-risk (HR) myelodysplastic syndromes (MDS). This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
Magrolimab is a first-in-class CD47 inhibitor antibody that has been shown basically to induce complete responses in a significant number of patients with higher-risk MDS once combined with azacitidine. And of course we have now ongoing randomized study to confirm those results called the Enhance trial. And we also have an oral version of decitabine and that’s already approved, which is a combination of decitabine with cedazuridine so that it can be taken orally...
Magrolimab is a first-in-class CD47 inhibitor antibody that has been shown basically to induce complete responses in a significant number of patients with higher-risk MDS once combined with azacitidine. And of course we have now ongoing randomized study to confirm those results called the Enhance trial. And we also have an oral version of decitabine and that’s already approved, which is a combination of decitabine with cedazuridine so that it can be taken orally. So with those two pieces of data, we decided to conduct a trial that combines Magrolimab with the oral decitabine and cedazuridine. So this will be a Phase II study, it’s going to be international – run in many countries – and it’s going to look, as a primary endpoint, at the response rate. But of course we are going to look at other endpoints, including survival outcomes. We are very excited with this study and it’s going to open hopefully in the next couple of weeks for enrolment.
Read more...
Disclosures
BMS, AbbVie, Takeda, Novartis, Aprea, Amgen, Otsuka, Gilead, Kura, Loxo Oncology, Geron, Mendus, Tyme: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees.
